Company
Every investor coverage indicates participated in a round Howard Hughes Medical Institute raised.
Companies Howard Hughes Medical Institute acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Prof Anna Marie Pyle | Investigator | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
Stories naming Howard Hughes Medical Institute. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Cancer biotech Amaroq Therapeutics appointed four experts to its advisory board as it moves toward clinical trials; the New Zealand company's backers include Brandon Capital, which reports $14m invested to date.
New Zealand biotech Amaroq Therapeutics reported early progress toward clinical trials and appointed four leading scientists to its scientific advisory board, strengthening its lncRNA cancer therapy programme.
Opal Therapeutics partners with Massachusetts General Hospital on an HIV immunotherapy collaboration as human trials begin in London; the biotech counts Alloy Ventures, Alta Partners and GBS Ventures among its backers.